
PUMA BIOTECHNOLOGY, INC. — Investor Relations & Filings
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer. The company's primary commercial product is Nerlynx® (neratinib), an FDA-approved oral medication for certain types of breast cancer. Its clinical pipeline includes alisertib, an investigational drug being evaluated in clinical trials for small cell lung cancer and metastatic breast cancer. The company's mission is to develop and commercialize innovative products to enhance cancer care.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer) | 2026-05-07 | English | |
| ARS - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer) | 2026-04-28 | English | |
| SCHEDULE 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject) | 2026-03-27 | English | |
| 10-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer) | 2026-02-26 | English | |
| 8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer) | 2026-02-26 | English | |
| 4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer) | 2026-02-21 | English |
Browse filings by year
17 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
11 filings
| |||||
| 43531573 | 8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer) | 2026-05-07 | English | ||
| 38160772 | ARS - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer) | 2026-04-28 | English | ||
| 33062747 | SCHEDULE 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject) | 2026-03-27 | English | ||
| 32891304 | 10-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer) | 2026-02-26 | English | ||
| 32891296 | 8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer) | 2026-02-26 | English | ||
| 32700165 | 4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer) | 2026-02-21 | English | ||
| 32700155 | 4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer) | 2026-02-21 | English | ||
| 32700152 | 4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer) | 2026-02-21 | English | ||
| 29414787 | 4 Filing | 2026-01-08 | English | ||
| 29414786 | 4 Filing | 2026-01-08 | English | ||
| 29414770 | 4 Filing | 2026-01-08 | English | ||
|
2025
4 filings
| |||||
| 12162691 | FORM 4 | 2025-11-13 | English | ||
| 12162694 | Regulatory Filings 2025 | 2025-11-12 | English | ||
| 12162697 | FORM 10-Q | 2025-11-06 | English | ||
| 12162702 | FORM 8-K | 2025-11-06 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Công ty Cổ phần Traphaco
Specializes in pharmaceutical R&D, manufacturing, and expor…
|
TRA | VN | Manufacturing |
|
Công ty Cổ phần Xuất nhập khẩu Y tế DOMESCO
Specializes in research, manufacturing, and distribution of…
|
DMC | VN | Manufacturing |
|
Công ty Cổ phần Y Dược phẩm Vimedimex
Pharmaceutical enterprise importing, exporting, and manufac…
|
VMD | VN | Manufacturing |
|
ConjuChem Biotechnologies Inc.
Develops long-acting therapeutic peptides using proprietary…
|
CJHMF | CA | Manufacturing |
|
Connect Biopharma Holdings Ltd
A clinical-stage biopharma developing therapies for T cell-…
|
CNTB | US | Manufacturing |
|
Consun Pharmaceutical Group Limited
Modern pharmaceutical enterprise specializing in Chinese Me…
|
1681 | KY | Manufacturing |
|
Context Therapeutics Inc.
Clinical-stage biopharma developing T cell engaging bispeci…
|
CNTX | US | Manufacturing |
|
Contineum Therapeutics, Inc.
Clinical-stage biopharma developing oral small molecule the…
|
CTNM | US | Manufacturing |
|
Coral Laboratories Ltd.
Develops, manufactures, and markets WHO-GMP pharmaceutical …
|
524506 | IN | Manufacturing |
|
Corbus Pharmaceuticals Holdings, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
CRBP | US | Manufacturing |
PUMA BIOTECHNOLOGY, INC. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33488/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33488 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33488 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33488 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33488}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for PUMA BIOTECHNOLOGY, INC. (id: 33488)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.